Intended for healthcare professionals

Letters Rivaroxaban: can we trust the evidence?

Questions about the reliability of ROCKET-AF anticoagulation data

BMJ 2016; 352 doi: (Published 23 February 2016) Cite this as: BMJ 2016;352:i1039
  1. Constantinos Christopoulos, physician and haematologist
  1. “A Fleming” Hospital, Athens 15127, Greece
  1. cgchrist{at}

Like Cohen, I also worry about the quality of evidence of the ROCKET-AF trial that led to regulatory approval of rivaroxaban for stroke prevention in non-valvular atrial fibrillation.1

In the warfarin treated control group, the mean time in therapeutic range (TTR) was reported to be …

View Full Text

Log in

Log in through your institution


* For online subscription